Confronting Intractable Diseases through Drug Discovery
-
Who We Are
Our company has taken on the challenge of developing new treatments for intractable diseases that have previously had no cure.
Established in October 2017 as a venture company spun out of Osaka University, we aim to support patients worldwide who suffer from these diseases and to advance the development of promising treatments.
We are committed not only to conducting research for the sake of research, but to creating medicines from Japan that can be applied in clinical practice to improve patients' lives.
-
R&D
Our company is advancing the development of pharmaceuticals targeting pathological periostin, based on our research on periostin. In particular, we are focusing on the development of novel therapies for metastatic and recurrent HER2-negative breast cancer, including triple-negative breast cancer (TNBC). TNBC is a particularly severe condition, with a high incidence in young women and a five-year survival rate of less than 50%. We are making steady progress in preparing for clinical trials, with the goal of developing new treatments at an early stage.
We possess several therapeutic neutralizing antibodies targeting pathological periostin and, in collaboration with Osaka University, are integrating cutting-edge technologies based on real-world clinical data to drive the development of innovative therapies.
Strengths
Strong Intellectual Property Portfolio Supporting Our Unique Technology
One of the key strengths of Periotherapia Co., Ltd. lies in its powerful intellectual property (IP) portfolio supporting our unique technologies. We have obtained numerous patents for the development of specific neutralizing antibodies targeting periostin, securing a competitive advantage. This IP portfolio not only protects our unique technologies, which cannot be easily replicated by others, but also lays the foundation for long-term market dominance. Additionally, through collaboration with leading research institutions such as Osaka University, we continue to integrate the latest technologies, further strengthening our IP portfolio and solidifying our foundation to provide new treatments for intractable diseases.
Development Based on Real-World Clinical Needs Through Collaboration with Academia and Integration of Cutting-Edge Technologies
We work closely with top academic institutions both in Japan and abroad, including Osaka University, to advance the development of treatments that are closely aligned with real-world clinical needs. This collaboration enables us to quickly incorporate innovative technologies based on actual clinical requirements. Through joint research with researchers, theoretical discoveries are translated into clinical applications, allowing us to develop therapies that integrate the latest technologies at an accelerated pace. As a result, we have built a solid foundation to provide patients with new treatment options.
